Anaconda Biomed Earns CE Mark for ANA5 Funnel Catheter

Anaconda Biomed has received CE mark certification for its ANA5 (advanced neurovascular access) funnel catheter, a mechanical thrombectomy device to treat ischemic stroke.

ANA5 maximizes clot capture with a vessel-matching diameter funnel. It also allows antegrade flow arrest and provides potential for flow reversal to boost aspiration-assisted clot retrieval. Through a unique, proprietary geometry, the company said ANA5 promotes improved clot capture and removal.

The device consists of a radiopaque nitinol brain funnel covered in a polymeric coating to enable local flow arrest.

The approval was based on clinical data from the recently published ANAIS study that showed high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, which is evaluating the impact of proximal flow arrest on reperfusion effectiveness. This is to support future regulatory submissions and commercialization efforts in the U.S.

“Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed that advances our mission to innovate in the interventional management of acute ischemic stroke,” said Trent Reutiman, CEO of Anaconda Biomed. “This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.”

“Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench,” added Anaconda Biomed co-founder Dr. Marc Ribo. “This is more than a regulatory milestone; it’s the moment where innovation becomes impact. We’re now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities.”